RenovaCare Inc RCAR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.35
- Bid/Ask
- $0.07 / $0.10
- Market Cap
- $8,735.24
- Volume/Avg
- 212 / 2,914
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1
- Website
- https://www.renovacareinc.com
Valuation
|
Metric
|
RCAR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RCAR
|
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.62 |
Interest Coverage | −4,984.74 |
Quick Ratio
RCAR
Profitability
|
Metric
|
RCAR
|
|---|---|
Return on Assets (Normalized) | −172.62% |
Return on Equity (Normalized) | −585.80% |
Return on Invested Capital (Normalized) | −358.50% |
Return on Assets
RCAR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vrzwjbchqk | Bhyqs | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vksgvkkwr | Rwtslk | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rltkmjdy | Lbkvyl | $98.8 Bil | |
MRNA
| Moderna Inc | Frwztyby | Ffnl | $38.8 Bil | |
ARGX
| argenx SE ADR | Flhycxvzv | Bvnv | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Bydfhgzm | Vxs | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xgbnswpl | Ktcdsv | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bcxjgxhy | Ckdgljw | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Stdbytdfdc | Slllbf | $12.4 Bil | |
INCY
| Incyte Corp | Csgysxjl | Nymyxlr | $11.9 Bil |